Jakavi 10mg

Jakavi 10mg is a prescription medication used to treat certain types of blood cancer, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). It is a JAK inhibitor that works by inhibiting the growth of cancer cells and reducing the production of new blood cells that can cause harm.

Composition:

• Jakavi 10mg: Ruxolitinib 10mg

Mechanism of Action:

Ruxolitinib, the active ingredient in Jakavi, is a JAK inhibitor that works by:

1. Inhibiting the growth of cancer cells by blocking the action of specific enzymes that promote cell growth and division.
2. Reducing the production of new blood cells that can cause harm, such as platelets, white blood cells, and red blood cells.
3. Inhibiting the activity of various signaling pathways that contribute to cancer cell growth and survival.

Indications:

Jakavi is approved for the treatment of:

1. Polycythemia vera (PV) in patients who are refractory or intolerant to hydroxyurea.
2. Essential thrombocythemia (ET) in patients who have had an inadequate response to previous treatment.
3. Primary myelofibrosis (PMF) in patients who are refractory or intolerant to hydroxyurea.

Dosage:

The recommended dosage of Jakavi is:

• 10mg orally twice daily, taken at the same time every day.
• The recommended duration of treatment is until disease progression or unacceptable toxicity.

Side Effects:

Common side effects of Jakavi include:

1. Nausea
2. Vomiting
3. Fatigue
4. Headache
5. Diarrhea
6. Abdominal pain
7. Skin rash
8. Hair loss
9. Muscle pain
10. Increased risk of bleeding or bruising

Recommendation:

Jakavi is recommended for patients who have been diagnosed with PV, ET, or PMF and have not responded to other treatments or have disease that has progressed after surgery and radiation therapy.

Important Note:

• Patients taking Jakavi should be closely monitored for signs of bleeding or bruising due to the risk of thrombocytopenia.
• Patients taking Jakavi should avoid taking medications that may increase the risk of bleeding or bruising.
• Pregnant or breastfeeding women should not use Jakavi, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Jakavi and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of kidney disease should be closely monitored for signs of worsening kidney function while taking Jakavi.
• Patients taking Jakavi should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase blood pressure.
• Patients with a history of heart disease or high blood pressure should be closely monitored while taking Jakavi.

Contraindications:

• Patients with severe liver disease or severe kidney disease should not use Jakavi.
• Patients who are allergic to ruxolitinib or any other component of Jakavi should not use it.
• Patients who are pregnant or breastfeeding should not use Jakavi.